Kevin J. Tam
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Journal: Endocrine-related cancer
Published: January 17, 2023
Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas?
Journal: Journal of applied biomedicine
Published: November 28, 2020
DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.
Journal: Clinical and experimental medicine
Published: July 15, 2020
Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics.
Journal: Frontiers in oncology
Published: March 10, 2019
Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.
Journal: International journal of molecular sciences
Published: January 01, 2019
Targeting Semaphorin 3C in Prostate Cancer With Small Molecules.
Journal: Journal of the Endocrine Society
Published: June 03, 2018
Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
Journal: European journal of medicinal chemistry
Published: May 02, 2018
Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Journal: Cancer letters
Published: April 03, 2018
SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.
Journal: EMBO molecular medicine
Published: January 20, 2018
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.
Journal: Molecular cancer therapeutics
Published: March 21, 2017
Last Updated: 09/26/2026